“RB-reactivator screening” as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist)

Sakai, Toshiyuki

Pharmacology & therapeutics (Oxford), 2022-08, Vol.236, p.108234-108234, Article 108234 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível